Delamanid
ANTIINFECTIVES FOR SYSTEMIC USE
Also known as: deltyba, OPC-67683
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Delamanid is a drug catalogued in DrugCentral. It was first approved by the EMA in 2013. Recorded indications include Drug resistant tuberculosis.
- Indications: Drug resistant tuberculosis.
- ATC code: J04AK06 (Other drugs for treatment of tuberculosis).
- Molecular formula: C25H25F3N4O6; molecular weight 534.49 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Drug resistant tuberculosis
Regulatory approvals (2)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2014-07-04 | PMDA | — | — | |
| 2013-11-22 | EMA | — | — |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
J04AK06 | ANTIINFECTIVES FOR SYSTEMIC USE › ANTIMYCOBACTERIALS › DRUGS FOR TREATMENT OF TUBERCULOSIS › Other drugs for treatment of tuberculosis |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Electrocardiogram QT prolonged | 680.3 |
| Neuropathy peripheral | 276.4 |
| Anaemia | 213.3 |
| Incorrect product administration duration | 128.4 |
| Vomiting | 128.2 |
| Off label use | 115.3 |
| Tuberculosis | 107.5 |
| Intentional product use issue | 88.8 |
| Hypokalaemia | 86.4 |
| Optic neuritis | 79.5 |
| Psychotic disorder | 71.3 |
| Drug resistance | 70.2 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Delamanid is on its molecule page.
| Molecular formula | C25H25F3N4O6 |
|---|---|
| Molecular weight | 534.49 g/mol |
| CAS number | 681492-22-8 |
| InChIKey | XDAOLTSRNUSPPH-XMMPIXPASA-N |
| PubChem CID | 6480466 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Delamanid used for?
DrugCentral lists the following indications for Delamanid: Drug resistant tuberculosis.
When was Delamanid first approved?
Delamanid was first approved by the EMA in 2013.
What is the chemical formula of Delamanid?
Delamanid has the molecular formula C25H25F3N4O6 and a molecular weight of 534.49 g/mol.
Browse: all drugs starting with D · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4819 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL218650 — compound record and bioactivity
- PubChem CID 6480466 — chemical identifiers
- DrugBank DB11637 — drug record
- FDA UNII 8OOT6M1PC7 — substance identity
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.